Goldman Sachs Raises Stake in Olema Pharmaceuticals, Inc. (OLMA)

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is among the best fast money stocks to buy now. During the first quarter, Goldman Sachs Group Inc. expanded its holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 93.6%. Following the purchase of 358,412 shares, the leading bank now owns 741,329 shares of the company’s stock, translating to an investment of $2,787,000 and an ownership of nearly 1.08%.

Oppenheimer is among the many research firms bullish on Olema Pharmaceuticals, Inc. (NASDAQ:OLMA). After the company’s collaboration with Pfizer, aiming to test Pfizer’s next-generation CDK4-selective drug atirmociclib in combination with Olema’s palazestrant, the research firm issued an ‘Outperform’ rating on the stock, along with a price target of $22.

This potential upside of over 130% is no accident, as many believe Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is strategically well-positioned with two key players in HR-positive breast cancer, with the company’s current palazestrant and ribociclib combination study with Novartis.

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is a California-based clinical-stage biopharmaceutical company developing and commercializing therapies for women’s cancers. Incorporated in 2006, the company is dedicated to impacting breast cancer.

While we acknowledge the potential of OLMA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than OLMA and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.